Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]
In development [GID-TA10398] Expected publication date: TBC
Search results
719 results
-
-
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
In development [GID-TA10633] Expected publication date: TBC
-
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]
In development [GID-TA10202] Expected publication date: TBC
-
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683
In development [GID-TA10537] Expected publication date: TBC
-
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]
In development [GID-TA10760] Expected publication date: TBC
-
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]
In development [GID-TA10761] Expected publication date: TBC
-
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]
Proposed [GID-TA10739] Expected publication date: TBC
-
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
In development [GID-TA10577] Expected publication date: 21 April 2021
-
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]
In development [GID-TA10523] Expected publication date: TBC
-
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]
In development [GID-TA10759] Expected publication date: TBC
-
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia [ID2708]
In development [GID-TA10588] Expected publication date: TBC
-
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
In development [GID-TA10539] Expected publication date: 15 December 2021
-
Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]
In development [GID-TA10566] Expected publication date: TBC
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]
In development [GID-TA10430] Expected publication date: TBC
-
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065
In development [GID-TA10385] Expected publication date: TBC
-
Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]
In development [GID-TA10572] Expected publication date: TBC
-
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Proposed [GID-TA10598] Expected publication date: TBC
-
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]
In development [GID-TA10342] Expected publication date: TBC
-
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]
In development [GID-TA10352] Expected publication date: 13 October 2021
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Proposed [GID-TA10700] Expected publication date: TBC
-
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]
In development [GID-TA10222] Expected publication date: TBC
-
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
In development [GID-TA10656] Expected publication date: 02 March 2022
-
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
In development [GID-TA10464] Expected publication date: TBC
-
Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]
In development [GID-TA10591] Expected publication date: TBC
-
Atherothrombotic events - vorapaxar [ID616]
In development [GID-TAG493] Expected publication date: TBC
-
Head and neck cancer - intensity modulated radiotherapy [ID15]
In development [GID-TAG397] Expected publication date: TBC
-
Glaucoma - lerdelimumab (CAT-152) [ID383]
In development [GID-TAG381] Expected publication date: TBC
-
Multiple sclerosis in adults: management
In development [GID-NG10153] Expected publication date: 20 July 2022
-
Idebenone for treating Duchenne muscular dystrophy ID1092
In development [GID-TA10310] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Proposed [GID-TA10741] Expected publication date: TBC
-
Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]
In development [GID-TA10649] Expected publication date: 22 September 2021
-
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610
In development [GID-TA10499] Expected publication date: TBC
-
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
In development [GID-TA10416] Expected publication date: TBC
-
OTL-200 for treating metachromatic leukodystrophy [ID1666]
In development [GID-HST10028] Expected publication date: 13 August 2021
-
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
In development [GID-TA10597] Expected publication date: 27 October 2021
-
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]
Proposed [GID-TA10666] Expected publication date: 26 August 2021
-
Atrial fibrillation - vernakalant [ID454]
In development [GID-TAG428] Expected publication date: TBC
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Proposed [GID-TA10536] Expected publication date: TBC
-
Conjunctivitis: antimicrobial prescribing
In development [GID-NG10166] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Proposed [GID-TA10757] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Proposed [GID-TA10758] Expected publication date: TBC
-
Carotuximab with pazopanib for treating advanced angiosarcoma ID1503
In development [GID-TA10401] Expected publication date: TBC
-
Asunercept for treating glioblastoma [1301]
In development [GID-TA10227] Expected publication date: TBC
-
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186
In development [GID-TA10289] Expected publication date: TBC
-
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
In development [GID-TA10225] Expected publication date: TBC
-
Kidney transplantation (rejection) - belatacept [ID87]
In development [GID-TAG239] Expected publication date: TBC
-
DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]
In development [GID-TA10143] Expected publication date: TBC
-
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
In development [GID-TA10261] Expected publication date: TBC
-
Binimetinib for treating melanoma [ID833]
In development [GID-TA10074] Expected publication date: TBC
-
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
In development [GID-TA10081] Expected publication date: TBC